Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by knoxt on Jan 27, 2022 1:50pm

Quiet here

THERALASE TECHNOLOGIES INC (CA: TLT)


          
Real-time  

Last: 0.335   Change: 0.000   Volume: 69,100   Last Trade: 12:33  

  Level ll Quote
  Bid   Ask
  Price   Total Size   # of Orders   Price   Total Size   # of Orders
$0.335 55500 3 $0.34 1500 1
$0.33 6500 2 $0.345 1000 1
$0.325 45500 5 $0.35 54500 2
$0.32 84000 5 $0.355 57500 2
$0.315 15000 2 $0.36 35500 2
$0.31 19000 4 $0.365 14000 2
$0.30 43500 1 $0.37 147500 5
$0.295 4000 1 $0.38 10500 2
$0.285 58000 2 $0.395 38000 3
$0.28 10000 1 $0.40 258500 8
 
Comment by 99942Apophis on Jan 27, 2022 2:12pm
Yes knoxt it is quiet and that's because we are all waiting for the anticipated results on patients that are pending in both 90 & 180 day results after we see what most are expecting then this volcano will blow and no more quiet. 
Comment by Legit62 on Jan 27, 2022 2:51pm
it's the lull before the storm, while we all sit here LONG!!!! waiting
Comment by CancerSlayer on Jan 27, 2022 5:36pm
  This currently dormant volcano will continue to get more active.  In the meantime, many investors simply don't fully grasp the significance of the current evaluable data....coming from an unoptimized cohort (unintended) & optimized cohort (intended).  My so-called inadvertent cohort comparison is clearly signaling to me strong efficacy with correct dosing.   Of ...more  
Comment by Legit62 on Jan 27, 2022 6:08pm
Having a medical  background, i really liked the way you explained what these trials have accomplished, im a long , big time holder and also have alot of faith in what this company will achieve. soon!!!!! The one thing that still amazes me is the low share volume for a company that will soon show the world it has a cure for cancer.
Comment by CancerSlayer on Jan 27, 2022 6:23pm
  Much appreciated...the low share volume has been a big plus for me : ) What others also may not realize is that there is no reason why a maintenance treatment cannot be used more than once...for those who continue to demonstrate residual, but non-progressing, CIS disease.  There may simply be a subset of patients who need an additional treatment (no more, no less)...all imo ...more  
Comment by 99942Apophis on Jan 27, 2022 7:18pm
Thanks CancerSlayer you're explanation are well appreciated, thumbs up!
Comment by Mikee3003 on Jan 27, 2022 8:09pm
Indeed CS additional TLT maintenace treatments will be investigated, just takes time to run through the trials. I'm going to use Rituximab as an example (one of the top selling oncology drugs with annual sale of approximately $8.5 billion, it is also the world's first onclogy monoclonal antibody therapy). My own personal experience with maintenance treatments has been with Rituxamab for ...more  
Comment by CancerSlayer on Jan 27, 2022 9:10pm
  Appreciate your example Mikee & wish you the best in your battle.  You bring up a great point...if all goes well, this current trial will likely be the first of very many.  I am hopeful TLT's ACT can be the WD-40 of cancer treatment...used alone, as an adjuvant/add-on, or as a combo treatment for many cancer indications...not to mention infections.  Good luck & ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250